VCN-X

VCN-X is a preclinical-stage, next-generation oncolytic adenovirus being developed by Theriva Biologics (formerly Synthetic Biologics). It is part of the VCN Bioscience platform, which focuses on developing oncolytic viruses that selectively replicate in and destroy tumor cells while modifying the tumor microenvironment to enhance therapeutic efficacy. As a next-generation candidate, VCN-X is designed to build upon the clinical findings of the company's lead asset, VCN-01, potentially incorporating advanced features for improved systemic administration, enhanced tumor selectivity, or the inclusion of therapeutic payloads designed to overcome immunosuppression. The specific therapeutic indications and molecular targets for VCN-X have not yet been publicly detailed in company disclosures.